6363461
Last Update Posted: 2025-04-24
Recruiting has ended
All Genders accepted | 18 Years + |
24 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of TDM-180935 in Atopic Dermatitis Patients
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
Protocol 239-13851-202 is a Phase 2a study entitled "A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients". Eligible subjects (24) in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups (low dose vs high dose vs placebo 1 vs placebo 2) and treated for 8 weeks. Eligible subjects (6) in the PK (pharmacokinetics) cohort will be treated with the high dose in an open label fashion.
Eligibility
Relevant conditions:
Atopic Dermatitis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Arthur P. Bertolino, MD, PhD, MBA
arthur.bertolino@innovationderm.com
+1 6169281145
Data sourced from ClinicalTrials.gov